SHR-4640: a "quiet asset" in Hengrui's chronic disease line — can the commercial platform amplify it into the next steady cash card?

Jiangsu Hengrui Pharmaceuticals had 2024 revenue of RMB 27.985 billion (+22.6% year on year), net profit attributable to shareholders of RMB 6.337 billion and R&D spending of RMB 8.228 billion; it has more than 11,800 sales staff, 17 marketed innovative drugs and more than 200 generic product specifications. After its secondary listing in Hong Kong in May 2025, the company has ample cash on its books and both A-share and H-share financing channels open. It is not a biotech "betting on one molecule", but a large Chinese pharma playing its cards simultaneously on three lines: "portfolio + commercial platform + globalization".

Hengrui's core therapeutic areas span oncology (camrelizumab, dalpiciclib, the SHR-A1811 ADC), anesthesia (remimazolam, ropivacaine), contrast agents, chronic metabolic disease (henagliflozin, retagliptin) and autoimmunity (vunakizumab). SHR-4640 falls in the chronic metabolic line, serving, together with SGLT2 and DPP-4 inhibitors, the overlapping populations of endocrinology, rheumatology and nephrology. More crucially — Hengrui's own febuxostat generic is already on sale, and the relationship with SHR-4640 is not cannibalization but a ladder of "first line, then second line" or "XO + URAT1 combination".

SHR-4640 is an oral once-daily selective inhibitor of URAT1 (SLC22A12); its public compound patent family corresponds to PCT/CN2016/080468 (priority CN201510216716.X, 2015-04-30), with compound protection running to around 2035 (patent-family basis; specific expiry dates vary by region and term extension). From the first Phase 1 enrollment (2017, CTR20170010) to completion of Phase 3 SHR4640-303 in August 2024 (CTR20191664), the China side took nearly ten years. In the published Phase 2, the proportions achieving sUA < 6 mg/dL at Week 5 with 5 mg / 10 mg QD were 32.5% and 72.5% respectively (benzbromarone control 61.5%) (Phase 2 published in Rheumatology, 2021); Phase 3 topline response rates have not yet been disclosed in a full journal article, and company statements indicate the primary endpoint was met. The China NDA was accepted by CDE in January 2025, and Hengrui's 2025 annual report lists the product (proposed name: ruzinurad sodium tablets) among projects expected to launch in 2026 (not yet approved; review uncertainty remains).

Place SHR-4640 in the global URAT1 matrix:

Global URAT1 inhibitor landscape comparison.

On the first-in-class / best-in-class / fast-follow scale, SHR-4640 belongs to neither of the first two — globally it is closer to "fast-follow with clean safety". Whether this positioning is good or bad is not absolute: the global premium for fast-follow is capped by dotinurad and verinurad, but in the Chinese market it enjoys the stacked fourfold advantage of the same mechanism, local data, a local team and room to maneuver in NRDL negotiations. Success in the Chinese market often depends not on being "first" but on "coverage".

The potential challenges that really deserve a red flag come from two sides: on one side, dotinurad has already launched first in China, with Eisai's medical and commercial teams capturing department awareness and retail channels; on the other, domestic peers such as ABP-671 are still following (HP501 has paused further development), and if one of them enters the NRDL first via conditional approval or expedited review, this product's window will be cut further. These are the two fronts SHR-4640 must face before formal approval.

The China NDA was accepted by CDE in January 2025 and is advancing in the standard review queue — it has not received any public Breakthrough Therapy or priority review designation. This is not surprising: hyperuricemia and gout have marketed treatments (including dotinurad), so they do not meet the BTD precondition of "seriously life-threatening with no available treatment". Standard review means a review duration floating in the 12–18-month range; Hengrui's 2025 annual report lists the product among projects expected to launch in 2026 (company statement; not yet approved; review uncertainty remains).

What deserves effort during the review window is not "can it be approved" but "can the label be approved broadly" — in particular: whether both 5 mg and 10 mg doses are approved together to serve populations with different sUA baselines, whether tophaceous gout and CKD subgroups can be covered, and whether label room for combination with febuxostat can be preserved. Label breadth directly determines post-launch prescribing boundaries and NRDL bargaining chips, and should be fought for repeatedly in the pre-NDA and review query stages, not patched after conditional approval.

On the data package side, the sample size, follow-up length and safety exposure of the China Phase 3 are sufficient for a single-country NDA; the main review query risks are concentrated in two points: first, whether statistical support for the 5 mg / 10 mg dose selection can sustain "simultaneous approval of both doses"; second, whether indirect comparisons with existing URAT1 / XO inhibitors can hold up in the pre-negotiation NRDL narrative. These are the two things most worth the medical affairs team's bets in the final 12 months before launch.

This section is the center of gravity of the whole analysis. The essential reason SHR-4640 is worth Hengrui continuing to push is not how strong its global differentiation is, but that it happens to grow in the soils Hengrui knows best — endocrinology, rheumatology, nephrology, chronic disease, retail; Hengrui has been covering these departments for twenty years, and the marginal promotion cost of adding a URAT1 is extremely low.

The first layer of leverage is hospital coverage. Hengrui's sales network already covers the endocrinology, rheumatology/immunology and nephrology departments of tertiary general hospitals; combined with the existing febuxostat generic and SGLT2 innovative drug channels, SHR-4640's path to hospital listing and formulary committee approval does not need new bridges; regional KOL and prescriber education can warm up 6 months before approval in 2026, pushing coverage in the first 12 months after launch to a class-leading level.

The second layer of leverage is the product portfolio. SHR-4640 does not need to build a separate "gout product story" — it slots straight into existing treatment pathways in Hengrui's chronic disease portfolio: the three-step ladder febuxostat → SHR-4640 → combination lets physicians move from first-line routine to second-line escalation to XO + URAT1 combination entirely within Hengrui's product sequence. This is a classic "product ladder positioning" — single-product ROI is not propped up by the product's own differentiation, but by prescription flow within the portfolio.

The third layer of leverage is the dual NRDL and retail channels. Gout is a typical long-term chronic medication; NRDL coverage can amplify dosing frequency and adherence, and dual retail channels (DTP and internet hospitals) can support out-of-pocket demand. The NRDL negotiation window is expected to open in the first adjustment cycle after approval (end-2026 or early 2027); a price cut in the 30%–50% range is the author's estimate (based on first-negotiation cuts for similar oral chronic disease drugs in recent years); as long as negotiation preserves NRDL status and retail prices are kept at a reasonable level, the product has the potential to reach annual peak sales on the order of RMB 1–2 billion in the Chinese market — this figure is also the author's directional estimate based on the Chinese market size of febuxostat and dotinurad, not company guidance and not a precise forecast.

The countervailing force to watch out for also comes from commercial platform leverage: volume-based procurement (VBP) price pressure. Once same-target assets such as Eisai's dotinurad and ABP-671 enter the NRDL one after another, the URAT1 mechanism class may enter a double squeeze of "intra-mechanism competition + VBP price pressure". At that point single-product ROI would switch from "commercial platform amplifies single product" to "commercial platform carries the portfolio" — which is why SHR-4640 must lock in market share as firmly as possible in the 2026–2027 window.

As an oral small molecule, SHR-4640's CMC complexity is far lower than that of antibodies and ADCs. Inferring from review practice, acceptance of a China NDA usually means the commercial batch process, stability data and polymorph selection are essentially finalized; Hengrui's own small-molecule lines (Lianyungang, Chengdu, etc.) have ample experience with such oral solid dosage forms (specific approvals and capacity allocation are not disclosed in public annual reports at the level of this product). This is the natural advantage of chronic disease small molecules — CMC is not the core hurdle; DDI and polymorphism are the frequent query points in CDE review.

What really needs to be settled strategically is not investing in own production lines for overseas supply. SHR-4640 has no public record of US or EU IND submissions, and overseas GMP inspections are not on the near-term calendar; if overseas rights are released through regional licensing in the future, the most rational overseas supply arrangement (in the author's judgment) is "partner takes over or contracts a CDMO", with Hengrui retaining Chinese API and formulation capacity. This "produce in China, don't invest overseas" posture is common practice for such assets — reserving marginal CMC investment for the true globalization priorities: ADCs, GLP-1s and bispecifics.

In Hengrui's 2024 and 2025 investor day narratives, the key products were the SHR-A1811 ADC, the HRS-7535 / HRS9531 GLP-1 series and the PD-1/L1 portfolio. SHR-4640 was not named, nor discussed as a "going-global priority" — its position in the portfolio is closer to a "steady-state product in the chronic metabolic line", not consuming much management attention but also not going to be downgraded or terminated. This position is actually the most comfortable inside a large pharma company: no budget needed to fight hard battles for it, yet it can steadily contribute China-side cash flow, a hidden pillar of portfolio health.

Hengrui's BD model over the past year or so offers several templates for SHR-4640: in May 2024 it licensed its GLP-1 portfolio to Hercules, a Bain Capital-backed NewCo (upfront of about US$110 million + milestones of about US$6 billion); in March 2025 it licensed the oral Lp(a) inhibitor HRS-5346 to Merck & Co./MSD (upfront of US$200 million + milestones of up to US$1.77 billion); plus several earlier regional out-licensing attempts. The common thread is that Hengrui has already run through the process of "how to split global rights, how to choose partners, how to quote valuations".

For SHR-4640, the most realistic path is not to copy the GLP-1 "single global partner" model (the global valuation anchor for this class is controlled by verinurad, and Hengrui would not get consideration comparable to GLP-1), but within 6–12 months after China approval in 2026, to carve out secondary regions such as Southeast Asia, the Middle East and Latin America and license them out separately to regional players. This "build the data package first, then monetize region by region" approach converts global value into multiple small upfronts + milestones without consuming Hengrui's overseas team. This is the secondary BD window and should be put on the agenda of portfolio governance meetings in 2026 H2.

Looking only at SHR-4640 as a single product, its story is easy to over- or underestimate: those who overestimate it stress the clean mechanism, comparable data and huge population; those who underestimate it stress that dotinurad launched first, verinurad is ahead and ABP-671 is close behind.

But viewed at the level of Hengrui's portfolio, its real value lies not in the single-product dimension but in the dimension of "marginal benefit of the commercial platform": Hengrui has already paid twenty years of costs for this soil, and every additional crop that needs no extra irrigation raises the yield of the whole field. SHR-4640 will most likely not become the next camrelizumab, but it has a chance to become a steady source of cash flow in the chronic disease line, and to monetize spillover value through regional licensing as multiple dispersed deals.

What Hengrui's globalization narrative ultimately assembles is not a single "moonshot", but the global offensive of its ADC / GLP-1 / PD-1 series plus the "portfolio cash flow" brought by assets like SHR-4640. The latter is less dazzling than the former, but equally indispensable.